New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab

I. Toboso, A. Tejeda-Velarde, R. Alvarez-Lafuente, R. Arroyo, H. Hegen, F. Deisenhammer, S. Sainz de la Maza, J.C. Alvarez-Cermeño, G. Izquierdo, D. Paramo, P. Oliva, B. Casanova, E. Agüera-Morales, D. Franciotta, M. Gastaldi, O. Fernández, P. Urbaneja, J.M. Garcia-Dominguez, F. Romero, A. LaroniA. Uccelli, A. Perez-Sempere, A. Saiz, Y. Blanco, D. Galimberti, E. Scarpini, C. Espejo, X. Montalban, L. Rasche, F. Paul, I. González, E. Álvarez, C. Ramo, A.B. Caminero, Y. Aladro, C. Calles, P. Eguía, A. Belenguer-Benavides, L. Ramió-Torrentà, E. Quintana, J.E. Martínez-Rodríguez, A. Oterino, C. López de Silanes, L.I. Casanova, L. Landete, J. Frederiksen, G. Bsteh, P. Mulero, M. Comabella, M.A. Hernández, M. Espiño, J.M. Prieto, D. Pérez, M. Otano, F. Padilla, J.A. García-Merino, L. Navarro, A. Muriel, L.C. Frossard, L.M. Villar

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Article number579438
JournalFrontiers in Neurology
Volume11
DOIs
Publication statusPublished - 2020

Keywords

  • biomarkers
  • demyelinating diseases
  • disease modifying treatments
  • multiple sclerosis
  • natalizumab
  • progressive multifocal leucoencephalopathy

Cite this